ISAL 2019 | Bob Löwenberg’s perspective on CAR-T and immunotherapy for AML

Name: Bob Löwenberg’s perspective on CAR-T and immunotherapy for AML
Uploaded: 2019-02-24T00:00:00.000Z
Duration: 1 min 28 s
Description: Bob Löwenberg, MD, PhD, of Erasmus University Medical Centre, Rotterdam, Netherlands, discusses his thoughts on CAR T-cell therapy and other immuno-oncology treatments for acute myeloid leukemia (AML). This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Bob Löwenberg • 24 Feb 2019

ISAL 2019

Acute Myeloid Leukemia Leukemia Antibodies CAR-T

Bob Löwenberg, MD, PhD, of Erasmus University Medical Centre, Rotterdam, Netherlands, discusses his thoughts on CAR T-cell therapy and other immuno-oncology treatments for acute myeloid leukemia (AML). This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.